EVOKE PHARMA INC's ticker is EVOK and the CUSIP is 30049G104. A total of 21 filers reported holding EVOKE PHARMA INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $21,000 | -32.3% | 42,793 | -22.7% | 0.00% | -33.3% |
Q4 2021 | $31,000 | +24.0% | 55,336 | +192.5% | 0.00% | +50.0% |
Q3 2021 | $25,000 | -46.8% | 18,918 | +3.2% | 0.00% | -60.0% |
Q4 2020 | $47,000 | -32.9% | 18,335 | -57.6% | 0.01% | -28.6% |
Q4 2019 | $70,000 | +4.5% | 43,210 | -59.8% | 0.01% | +75.0% |
Q2 2019 | $67,000 | -43.2% | 107,438 | +36.4% | 0.00% | -42.9% |
Q1 2019 | $118,000 | +47.5% | 78,787 | +195.2% | 0.01% | +40.0% |
Q3 2018 | $80,000 | +105.1% | 26,686 | +70.0% | 0.01% | +150.0% |
Q2 2018 | $39,000 | -18.8% | 15,695 | -26.9% | 0.00% | -33.3% |
Q4 2017 | $48,000 | -63.6% | 21,457 | -45.7% | 0.00% | -57.1% |
Q3 2017 | $132,000 | – | 39,489 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Wambolt & Associates, LLC | 32,000 | $113,000 | 0.09% |
Cetera Advisor Networks LLC | 30,260 | $107,000 | 0.00% |
Creative Planning | 100,000 | $354,000 | 0.00% |
OPTIMUM INVESTMENT ADVISORS | 800 | $3,000 | 0.00% |
Lindbrook Capital, LLC | 1,000 | $4,000 | 0.00% |
NORTHERN TRUST CORP | 37,438 | $133,000 | 0.00% |
CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
GEODE CAPITAL MANAGEMENT, LLC | 188,514 | $667,000 | 0.00% |
CITIGROUP INC | 500 | $2,000 | 0.00% |
GOLDMAN SACHS GROUP INC | 35,174 | $125,000 | 0.00% |